ALPN News and Press, Alpine Immune Sciences Inc.

FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...

2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-10 12:44:07 ET More on Alpine Immune Sciences Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences Vertex To Buy Alpine Immune - Why This Deal Feels Sli...

2024-05-09 17:50:00 ET More on Alpine Immune Sciences Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences Vertex To Buy Alpine Immune - Why This Deal Feels Sli...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-09 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is the focus of IBN's latest stock spotlight. The company's shares have moved 0% on the day to $64.64. Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.02% on the day to $64.6. Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapi...

2024-04-29 07:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...